Kathryn Wheeler PharmD, BCPS

Kathryn Wheeler, PharmD, BCPS, is an associate dean for academic affairs and clinical associate professor at the University of Connecticut School of Pharmacy.

Articles

Novel antifungal treatment approved for vaginal candidiasis

July 07, 2021

On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.